These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37660554)

  • 1. Generation of an induced pluripotent stem cell line (ESi107-A) from a transthyretin amyloid cardiomyopathy (ATTR-CM) patient carrying a p.Ser43Asn mutation in the TTR gene.
    Montero-Calle P; Flandes-Iparraguirre M; Kuebler B; Arán B; Larequi E; Anaut I; Coppiello G; Aranguren XL; Veiga A; Elorz MTB; de Yébenes MG; Gavira JJ; Prósper F; Iglesias-García O; Vega MMM
    Stem Cell Res; 2023 Sep; 71():103189. PubMed ID: 37660554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of an induced pluripotent stem cell line PUMCHi004-A from a hereditary transthyretin amyloid cardiomyopathy patient with transthyretin (TTR) p.Asp38Asn mutation.
    He S; Jin Y; Tian Z; Hua T; Xing H; Zhuang S; He X; Li H; Wang L; Zhang S
    Stem Cell Res; 2020 Dec; 49():102022. PubMed ID: 33038745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of an induced pluripotent stem cell line from a patient with hereditary transthyretin amyloidosis carrying transthyretin (TTR) mutation p.Phe53Val.
    Shan H; Ye J; Hai Ping X; XinYue H; ShuYang Z
    Stem Cell Res; 2020 Oct; 48():101940. PubMed ID: 32858486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation.
    Bonilauri B; Shin HS; Htet M; Yan CD; Witteles RM; Sallam K; Wu JC
    Stem Cell Res; 2023 Oct; 72():103215. PubMed ID: 37788558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of two induced pluripotent stem cell lines from hereditary amyloidosis patients with polyneuropathy carrying heterozygous transthyretin (TTR) mutation.
    Melesio J; Bonilauri B; Li A; Pang PD; Liao R; Witteles RM; Wu JC; Sallam K
    Stem Cell Res; 2024 Feb; 74():103265. PubMed ID: 38100909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease.
    Giadone RM; Liberti DC; Matte TM; Rosarda JD; Torres-Arancivia C; Ghosh S; Diedrich JK; Pankow S; Skvir N; Jean JC; Yates JR; Wilson AA; Connors LH; Kotton DN; Wiseman RL; Murphy GJ
    Stem Cell Reports; 2020 Aug; 15(2):515-528. PubMed ID: 32735824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
    Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC
    Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.
    Tini G; Vianello PF; Gemelli C; Grandis M; Canepa M
    J Cardiovasc Transl Res; 2019 Dec; 12(6):514-516. PubMed ID: 30604309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
    Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers.
    Ranløv I; Alves IL; Ranløv PJ; Husby G; Costa PP; Saraiva MJ
    Am J Med; 1992 Jul; 93(1):3-8. PubMed ID: 1626570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis.
    Leung A; Nah SK; Reid W; Ebata A; Koch CM; Monti S; Genereux JC; Wiseman RL; Wolozin B; Connors LH; Berk JL; Seldin DC; Mostoslavsky G; Kotton DN; Murphy GJ
    Stem Cell Reports; 2013; 1(5):451-63. PubMed ID: 24286032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
    Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT
    Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.